Abstract Details

Title A Clinical Prognostic Scoring System for Neurocysticercosis

Topic Global Health

Presentation(s) P04 - (-)

Poster/Presentation
Number 236

Objective

Background BACKGROUND: Infection of the human nervous system by T.solium larvae (neurocysticercosis) is a very common event in endemic regions, where symptomatic NCC accounts for approximately one third of seizure disorders and contributes to other neurological sequelae that result from the immunological reaction of the host against cysticerci, such reaction is largely unpredictable and accounts for the therapeutic and prognostic uncertainty that still remains around this disease.

Design/Methods DESIGN/METHODS: The scale was obtained in 293 consecutive patients fulfilling criteria for neurocysticercosis evaluated at our center. Outcome was assessed at 3 months as the number of patients with neurological deficit due to the parasitosis. By a preliminary univariate analysis, 14 of 42 baseline variables were found to be associated with the development of neurological sequelae. Subsequent multivariable analyses led to a final model of six dichotomous factors.

Results RESULTS: Each of the found factors was assigned a score based on their beta coefficient: Seizures (-1 point) or headache (1 point) as initial manifestation of neurocysticercosis, leukocyte count above 12x109/L (-1 point), presence of six to ten parasites (-1 point), subarachnoid localization of parasites (-1 point) and the use of anti-helminthic drugs (1 point). Among 113 patients with scores -4 to -1, 79.6% developed neurological deficits. With 1-2 scores, 64.6% of the patients recovered completely, overall accuracy of prediction 74.7%, area under ROC curve = 0.722 (95% Confidence Interval, 0.664-0.780, p<0.0001).

Conclusions CONCLUSIONS: In patients with neurocysticercosis, the presence of seizures, headache, leukocytosis and a moderate number of parasites with subarachnoid localization allow a simple and accurate prediction of the development of neurological sequelae due to this highly prevalent disease.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Elizabeth Soto Cabrera, MD (Neurodurango)	No disclosure on file
Fernando Zermeno, MD (Calz Mexico Xochimilco 4900)	No disclosure on file
	No disclosure on file
	No disclosure on file
Vicente J. Guerrero, MD (Instituto Nacional de Neurologia y Neurocirug)	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��